Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Laura Rabinovich"'
Autor:
Frank Schneider, Margaret Bradbury, Thomas A. Baillie, David Stamler, Edward Hellriegel, Donna S. Cox, Pippa S. Loupe, Juha‐Matti Savola, Laura Rabinovich‐Guilatt
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 4, Pp 707-717 (2020)
Deutetrabenazine (Austedo, Teva Pharmaceuticals) is a deuterated form of tetrabenazine. It is the first deuterated drug to receive US regulatory approval and is approved for treatment of chorea in Huntington’s disease and tardive dyskinesia. Two or
Externí odkaz:
https://doaj.org/article/488fd588e08e462d8e40b79611ffd5c1
Autor:
Eva-Maria Sunzel, Laura Rabinovich-Guilatt, Malini Iyengar, Debra Ruffo, Maria Gutierrez, Mark Forrest Gordon, Giulia Ghibellini
Publikováno v:
Sunday, April 23.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c81c46ffe4f9a294cbbc3a756fe1c757
https://doi.org/10.1212/wnl.0000000000202209
https://doi.org/10.1212/wnl.0000000000202209
Autor:
Eva-Maria Sunzel, Giulia Ghibellini, Malini Iyengar, Maria Gutierrez, Debra Ruffo, Mark Forrest Gordon, Laura Rabinovich-Guilatt
Publikováno v:
Sunday, April 23.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9eddbfac778fffa5c7ce9856bf63ec81
https://doi.org/10.1212/wnl.0000000000202218
https://doi.org/10.1212/wnl.0000000000202218
Autor:
Frank Schneider, Borje Darpo, Pippa S. Loupe, Hongqi Xue, Helena Knebel, Maria Gutierrez, Mark Forrest Gordon, Laura Rabinovich‐Guilatt
Publikováno v:
Clinical pharmacology in drug developmentReferences. 12(1)
Deutetrabenazine (Austedo) is indicated in adults for chorea associated with Huntington disease and tardive dyskinesia. Escalating deutetrabenazine doses were administered to healthy volunteers who were cytochrome P450 2D6 extensive/intermediate meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5f588eb2485a61605abeb0cfd558235
https://pubmed.ncbi.nlm.nih.gov/36098670
https://pubmed.ncbi.nlm.nih.gov/36098670
Autor:
Edward T. Hellriegel, Mark Forrest Gordon, David Stamler, Margaret Bradbury, Pippa S. Loupe, Donna S. Cox, Laura Rabinovich-Guilatt, Frank Schneider, Juha-Matti Savola
Publikováno v:
Clinical Pharmacology in Drug Development
Deutetrabenazine (Austedo, Teva), an approved treatment of chorea in Huntington's disease and tardive dyskinesia in adult patients, is a rationally designed deuterated form of tetrabenazine. Two studies assessed the pharmacokinetics and safety of deu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e54d6898ca61ef367ef6156dbacbd254
https://doi.org/10.1002/cpdd.882
https://doi.org/10.1002/cpdd.882
Autor:
Michael R. Hayden, Osama Sabri, Mark Forrest Gordon, Laura Rabinovich, Marianne Patt, Henryk Barthel, Michael Rullmann, Andreas Kluge, Gina Pastino, Georg Becker, Doug Marsteller, Swen Hesse, Helena Knebel, Peter Brust, Thilo Gerhards, Juha-Matti Savola, Marcus Bronzel, Philipp Meyer, Ole Voges, Michal Geva, Igor D. Grachev, Franziska Zientek, Maria Strauss, Bernhard Sattler
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging 48(2021), 1103-1115
European Journal of Nuclear Medicine and Molecular Imaging 48(2021), 1103-1115
Pridopidine is an investigational drug in late stage development for the treatment of Huntington disease and originally postulated to act as dopamine stabilizer by modulating dopamine-dependent motor behavior. However, preclinical studies show pridop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4137f555b5abb99b82655a00e1f0ced7
http://europepmc.org/articles/PMC8041674
http://europepmc.org/articles/PMC8041674
Autor:
Andrijana Radivojevic, Pippa S. Loupe, Michael Brennan, Xiaoping Ning, Michael Gillespie, Orit Cohen-Barak, Andrew H. Ahn, Yoel Kessler, Aksana Jones, Michele Rasamoelisolo, Laura Rabinovich-Guilatt, Jill Fiedler-Kelly, Dikla Gutman, Micha Levi, Hussein Hallak
Publikováno v:
Cephalalgia : an international journal of headache. 41(10)
Background Potential fremanezumab doses for pediatric patients were evaluated using pharmacokinetic modeling and simulation. An open-label phase 1 pharmacokinetic and safety study was conducted in pediatric patients with migraine. This study’s resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52808ded1741d75d6d3addb117322f06
https://pubmed.ncbi.nlm.nih.gov/34000848
https://pubmed.ncbi.nlm.nih.gov/34000848
Autor:
Shawn Li, Honglue Shen, Irina Cherniakov, Ryan Tiver, Hussein Hallak, Michael Smith, Ofer Spiegelstein, Pippa S. Loupe, Yoel Kessler, Laura Rabinovich-Guilatt, Michael Gillespie, Maria Gutierrez, Orit Cohen-Barak, Michele Rasamoelisolo
Publikováno v:
Clinical Pharmacology in Drug Development
Fremanezumab (AJOVY; Teva Pharmaceutical Industries Ltd, Netanya, Israel), approved for the preventive treatment of migraine, is available as a subcutaneous injection either once a month or once every 3 months using an autoinjector or a prefilled syr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5b185b3a69b852e709c6261a04bed58
https://pubmed.ncbi.nlm.nih.gov/33411992
https://pubmed.ncbi.nlm.nih.gov/33411992
Autor:
Liat Adar, Jill B Conner, Laura Rabinovich-Guilatt, Lindsay Janka, William Zarycranski, Jeffrey Dragone
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 55:931-938
Objective Difficulty swallowing pills can compromise pain control in painful musculoskeletal disorders. This open-label, 2-period crossover study assessed pharmacokinetics and safety of cyclobenzaprine extended-release (CER) 30-mg capsule contents sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96fd34cadb5c7c451cff77590fbe3b80
https://doi.org/10.5414/cp203059
https://doi.org/10.5414/cp203059
Autor:
William Tracewell, Murray P. Ducharme, Mona Darwish, Laura Rabinovich-Guilatt, Sally Selim, Philippe Colucci, Ofer Spiegelstein, Richard Malamut, Ronghua Yang, Mary Bond, Philmore Robertson
Publikováno v:
Clinical Drug Investigation. 37:1153-1163
Food intake can alter the pharmacokinetics of certain medications, including changes in their oral bioavailability, which is of particular concern for extended-release (ER) opioids because of the high drug loads. Two randomized, open-label studies as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b779fa3f68f71975bab5b4a4aa92933c
https://doi.org/10.1007/s40261-017-0575-3
https://doi.org/10.1007/s40261-017-0575-3